AIM ImmunoTech is trading 15% down at $0.22 after no clear company-specific catalyst was identified for August 14, 2026.

  • Recent coverage focused on August 10 second-quarter results and progress toward Phase 3 development; the final DURIPANC patient milestone was previously announced.
  • Available market coverage reports no specific announcement explaining the decline; broader biotech-market evidence does not establish a sector-wide cause.
  • Recent volatility included declines on August 10 and August 14; confidence in the catalyst assessment is low.